First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia

被引：6

作者：

Argyropoulos, Kimon V. ^{[1
]}

Lia, M. ^{[2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Program Immunol, 408 East 69th St, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, Dept Med, 1275 York Ave, New York, NY 10065 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2018年 / 32卷 / 05期

关键词：

Waldenstrom macroglobulinemia; BTK; Ibrutinib; Second-generation BTK inhibitors; B-CELL-RECEPTOR; ATRIAL-FIBRILLATION; GENE REARRANGEMENT; SOMATIC MUTATION; CLINICAL-TRIAL; IBRUTINIB USE; ACTIVATION; BTK; RESISTANCE; MYD88;

D O I：

10.1016/j.hoc.2018.05.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Waldenstrom macroglobulinemia (WM) is an indolent B-cell lymphoma that is heavily dependent on Bruton tyrosine kinase (BTK) hyperactivation. Ibrutinib is a first-generation BTK inhibitor that has shown high activity and durable responses in patients with relapsed/refractory WM. Newer and more selective BTK inhibitors are currently being tested in several clinical trials and are expected to address the toxicity and the acquired resistance observed in patients receiving ibrutinib. Updates on ibrutinib and second-generation BTK inhibitors are summarized in this article.

引用

页码：853 / +

页数：13

共 63 条

[31] Ibrutinib for patients with rituximab-refractory Waldenstrm's macro globulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial [J].

Dimopoulos, Meletios A. ;

Trotman, Judith ;

Tedeschi, Alessandra ;

Matous, Jeff Rey V. ;

Macdonald, David ;

Tam, Constantine ;

Tournilhac, Olivier ;

Ma, Shuo ;

Oriol, Albert ;

Heffner, Leonard T. ;

Shustik, Chaim ;

Garcia-Sanz, Ramon ;

Cornell, Robert F. ;

de Larrea, Carlos Fernandez ;

Castillo, Jorge J. ;

Granell, Miquel ;

Kyrtsonis, Marie-Christine ;

Leblond, Veronique ;

Symeonidis, Argiris ;

Kastritis, Efstathios ;

Singh, Priyanka ;

Li, Jianling ;

Graef, Thorsten ;

Bilotti, Elizabeth ;

Treon, Steven ;

Buske, Christian .

LANCET ONCOLOGY, 2017, 18 (02) :241-250

[32] Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes [J].

Dubovsky, Jason A. ;

Beckwith, Kyle A. ;

Natarajan, Gayathri ;

Woyach, Jennifer A. ;

Jaglowski, Samantha ;

Zhong, Yiming ;

Hessler, Joshua D. ;

Liu, Ta-Ming ;

Chang, Betty Y. ;

Larkin, Karilyn M. ;

Stefanovski, Matthew R. ;

Chappell, Danielle L. ;

Frissora, Frank W. ;

Smith, Lisa L. ;

Smucker, Kelly A. ;

Flynn, Joseph M. ;

Jones, Jeffrey A. ;

Andritsos, Leslie A. ;

Maddocks, Kami ;

Lehman, Amy M. ;

Furman, Richard ;

Sharman, Jeff ;

Mishra, Anjali ;

Caligiuri, Michael A. ;

Satoskar, Abhay R. ;

Buggy, Joseph J. ;

Muthusamy, Natarajan ;

Johnson, Amy J. ;

Byrd, John C. .

BLOOD, 2013, 122 (15) :2539-2549

[33] Requirement for CARMA1 in antigen receptor-induced NF-κB activation and lymphocyte proliferation [J].

Egawa, T ;

Albrecht, B ;

Favier, B ;

Sunshine, MJ ;

Mirchandani, K ;

O'Brien, W ;

Thome, M ;

Littman, DR .

CURRENT BIOLOGY, 2003, 13 (14) :1252-1258

[34] Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): An eastern cooperative oncology group study (E3A98) [J].

Gertz, MA ;

Rue, M ;

Blood, E ;

Kaminer, LS ;

Vesole, DH ;

Greipp, PR .

LEUKEMIA & LYMPHOMA, 2004, 45 (10) :2047-2055

[35] RETRACTED: MyD88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction (Retracted Article) [J].

Gray, P ;

Dunne, A ;

Brikos, C ;

Jefferies, CA ;

Doyle, SL ;

O'Neill, LAJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (15) :10489-10495

[36] Ibrutinib discontinuation in Waldenstrom macroglobulinemia: Etiologies, outcomes, and IgM rebound [J].

Gustine, Joshua N. ;

Meid, Kirsten ;

Dubeau, Toni ;

Severns, Patricia ;

Hunter, Zachary R. ;

Guang, Yang ;

Xu, Lian ;

Treon, Steven P. ;

Castillo, Jorge J. .

AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (04) :511-517

[37] The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy [J].

Honigberg, Lee A. ;

Smith, Ashley M. ;

Sirisawad, Mint ;

Verner, Erik ;

Loury, David ;

Chang, Betty ;

Li, Shyr ;

Pan, Zhengying ;

Thamm, Douglas H. ;

Miller, Richard A. ;

Buggy, Joseph J. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (29) :13075-13080

[38] The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis [J].

Hunter, Zachary R. ;

Xu, Lian ;

Yang, Guang ;

Zhou, Yangsheng ;

Liu, Xia ;

Cao, Yang ;

Manning, Robert J. ;

Tripsas, Christina ;

Patterson, Christopher J. ;

Sheehy, Patricia ;

Treon, Steven P. .

BLOOD, 2014, 123 (11) :1637-1646

[39] Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry [J].

Irish, Jonathan M. ;

Czerwinski, Debra K. ;

Nolan, Garry P. ;

Levy, Ronald .

JOURNAL OF IMMUNOLOGY, 2006, 177 (03) :1581-1589

[40] Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation [J].

Kamel, S. ;

Horton, L. ;

Ysebaert, L. ;

Levade, M. ;

Burbury, K. ;

Tan, S. ;

Cole-Sinclair, M. ;

Reynolds, J. ;

Filshie, R. ;

Schischka, S. ;

Khot, A. ;

Sandhu, S. ;

Keating, M. J. ;

Nandurkar, H. ;

Tam, C. S. .

LEUKEMIA, 2015, 29 (04) :783-787

← 1 2 3 4 5 6 7 →